Search This Blog

Tuesday, November 5, 2019

Blueprint Medicines EPS beats by $0.26, beats on revenue

Blueprint Medicines  (NASDAQ:BPMC): Q3 GAAP EPS of -$1.93 beats by $0.26.
Revenue of $9.14M (+730.9% Y/Y) beats by $6.29M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)